146 related articles for article (PubMed ID: 27402144)
1. Early treatment for high-risk smouldering myeloma: has the time come?
Ludwig H
Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
[No Abstract] [Full Text] [Related]
2. Early intervention effective in smouldering multiple myeloma.
Gourd E
Lancet Oncol; 2019 Dec; 20(12):e666. PubMed ID: 31679982
[No Abstract] [Full Text] [Related]
3. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
Sørrig R
Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
[No Abstract] [Full Text] [Related]
4. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
Chakraborty R
Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
[No Abstract] [Full Text] [Related]
5. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
Soomro MA; Hoffman J; Goodman AM; Sborov DW; Mohyuddin GR
Br J Haematol; 2022 Jun; 197(6):e86-e88. PubMed ID: 35229286
[No Abstract] [Full Text] [Related]
6. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
[No Abstract] [Full Text] [Related]
7. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
[No Abstract] [Full Text] [Related]
8. The impact of CD56 expression in smoldering myeloma patients on early progression.
Notarfranchi L; Segreto R; Vescovini R; Dalla Palma AB; Marchica V; Burroughs-Garcia J; Toscani D; Todaro G; Raimondi V; Iannozzi NT; Bonomini S; Sammarelli G; Craviotto L; Pedrazzoni M; Storti P; Giuliani N
Hematol Oncol; 2023 Aug; 41(3):587-589. PubMed ID: 36441875
[No Abstract] [Full Text] [Related]
9. Population screening for smoldering multiple myeloma reveals high prevalence.
Nat Med; 2023 Feb; 29(2):313-314. PubMed ID: 36755165
[No Abstract] [Full Text] [Related]
10. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
12. Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828-838.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929433
[No Abstract] [Full Text] [Related]
13. Smoldering Myeloma and the Art of War.
Lonial S; Dhodapkar MV; Rajkumar SV
J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
[No Abstract] [Full Text] [Related]
14. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
Gertz MA; Vaxman I
Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
[No Abstract] [Full Text] [Related]
15. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
[No Abstract] [Full Text] [Related]
16. Regression of smoldering myeloma with treatment of Gaucher disease.
Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
[No Abstract] [Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
18. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
[No Abstract] [Full Text] [Related]
19. Successful treatment of systemic sclerosis coexisting with smoldering myeloma.
Smoleńska Ż; Gogulska Z; Dorniak K; Zdrojewski Z
Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34698468
[No Abstract] [Full Text] [Related]
20. Calculated Globulin as a potential screening tool for paraproteinemia to aid in the early diagnosis of Multiple Myeloma.
O'Brien A; Bransfield A; O'Halloran F; Mykytiv V
Clin Biochem; 2023 Jun; 116():113-119. PubMed ID: 37119921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
